Linked Life Data

18256749

Source:http://linkedlifedata.com/resource/pubmed/id/18256749

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-2-7
pubmed:abstractText
Antidiabetic activity of a new ultralow-dose preparation of antibodies to insulin receptor beta-subunit was revealed on the model of streptozotocin diabetes in rats: treatment with this preparation in a daily dose of 2.5 ml/kg (for 50 days through a gastric tube) normalized blood glucose level, restored glucose tolerance in the oral glucose test and body weight gain, and improved animal survival. By its hypoglycemic activity and effect on glucose tolerance the preparation was not inferior to classical drugs for the treatment of types 1 and 2 diabetes mellitus insulin (12 U/kg) and glybenclamide (8 mg/kg).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0007-4888
pubmed:author
pubmed:issnType
Print
pubmed:volume
144
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
46-8
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Study of antidiabetic activity of a new ultralow-dose antibody preparation on the model of streptozotocin diabetes in rats.
pubmed:affiliation
Volgograd State Medical University, Russian Ministry of Health, Moscow.
pubmed:publicationType
Journal Article